Checkpoint Therapeutics Performance
| CKPTDelisted Stock | USD 4.26 0.02 0.47% |
The firm shows a Beta (market volatility) of -2.7, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Checkpoint Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Checkpoint Therapeutics is expected to outperform it. Checkpoint Therapeutics right now shows a risk of 0.0%. Please confirm Checkpoint Therapeutics standard deviation, expected short fall, period momentum indicator, as well as the relationship between the maximum drawdown and rate of daily change , to decide if Checkpoint Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Checkpoint Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Checkpoint Therapeutics is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Checkpoint |
Checkpoint Therapeutics Relative Risk vs. Return Landscape
If you would invest 426.00 in Checkpoint Therapeutics on November 8, 2025 and sell it today you would earn a total of 0.00 from holding Checkpoint Therapeutics or generate 0.0% return on investment over 90 days. Checkpoint Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Checkpoint, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Checkpoint Therapeutics Target Price Odds to finish over Current Price
The tendency of Checkpoint Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.26 | 90 days | 4.26 | about 22.81 |
Based on a normal probability distribution, the odds of Checkpoint Therapeutics to move above the current price in 90 days from now is about 22.81 (This Checkpoint Therapeutics probability density function shows the probability of Checkpoint Stock to fall within a particular range of prices over 90 days) .
Checkpoint Therapeutics Price Density |
| Price |
Predictive Modules for Checkpoint Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Checkpoint Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Checkpoint Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Checkpoint Therapeutics is not an exception. The market had few large corrections towards the Checkpoint Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Checkpoint Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Checkpoint Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.94 | |
β | Beta against Dow Jones | -2.7 | |
σ | Overall volatility | 0.51 | |
Ir | Information ratio | 0.10 |
Checkpoint Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Checkpoint Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Checkpoint Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Checkpoint Therapeutics is not yet fully synchronised with the market data | |
| Checkpoint Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 41 K. Net Loss for the year was (56.24 M) with loss before overhead, payroll, taxes, and interest of (31.4 M). | |
| Checkpoint Therapeutics currently holds about 30.89 M in cash with (31.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Roughly 14.0% of the company shares are held by company insiders |
Checkpoint Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Checkpoint Stock often depends not only on the future outlook of the current and potential Checkpoint Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Checkpoint Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 39.7 M | |
| Cash And Short Term Investments | 6.6 M |
Checkpoint Therapeutics Fundamentals Growth
Checkpoint Stock prices reflect investors' perceptions of the future prospects and financial health of Checkpoint Therapeutics, and Checkpoint Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Checkpoint Stock performance.
| Return On Equity | -18.7 | |||
| Return On Asset | -1.53 | |||
| Current Valuation | 337.66 M | |||
| Shares Outstanding | 86.32 M | |||
| Price To Earning | (7.60) X | |||
| Price To Book | 22.75 X | |||
| Price To Sales | 9,042 X | |||
| Revenue | 41 K | |||
| EBITDA | (56.17 M) | |||
| Cash And Equivalents | 30.89 M | |||
| Cash Per Share | 0.33 X | |||
| Total Debt | 20.1 M | |||
| Debt To Equity | 0.1 % | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (31.1 M) | |||
| Earnings Per Share | (1.28) X | |||
| Total Asset | 7.47 M | |||
| Retained Earnings | (370.57 M) | |||
| Current Asset | 46.85 M | |||
| Current Liabilities | 2.89 M | |||
About Checkpoint Therapeutics Performance
Assessing Checkpoint Therapeutics' fundamental ratios provides investors with valuable insights into Checkpoint Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Checkpoint Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc. Checkpoint Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Things to note about Checkpoint Therapeutics performance evaluation
Checking the ongoing alerts about Checkpoint Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Checkpoint Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Checkpoint Therapeutics is not yet fully synchronised with the market data | |
| Checkpoint Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 41 K. Net Loss for the year was (56.24 M) with loss before overhead, payroll, taxes, and interest of (31.4 M). | |
| Checkpoint Therapeutics currently holds about 30.89 M in cash with (31.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Roughly 14.0% of the company shares are held by company insiders |
- Analyzing Checkpoint Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Checkpoint Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Checkpoint Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Checkpoint Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Checkpoint Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Checkpoint Therapeutics' stock. These opinions can provide insight into Checkpoint Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Checkpoint Stock
If you are still planning to invest in Checkpoint Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Checkpoint Therapeutics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |